Top-News
Pharmazeutika Großbritannien

Amarin News

Aktie
WKN:  A0NBNG ISIN:  US0231112063 US-Symbol:  AMRN
0,81 €
-0,015 €
-1,82%
10.05.24 18:49:11
Handeln Depot/Watchlist
Aktienanzahl *
407,78 Mio.
Marktkapitalisierung *
332,83 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 26.06.2023

Amarin News

10.01.24 - PR Newswire
Thinking about buying stock in Clearmind Medicine, Bitfarms, Safety Shot, Cellectar Biosciences, or Amarin Corporation?
Thinking about buying stock in Clearmind Medicine, Bitfarms, Safety Shot, Cellectar Biosciences, or Amarin Corporation? PR Newswire
02.08.23 - GlobeNewswire
Amarin Reports Second Quarter 2023 Financial Results
-- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and ...
31.07.23 - GlobeNewswire
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region
26.07.23 - GlobeNewswire
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for ...
25.07.23 - GlobeNewswire
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
-- Spain’s Drug Pricing Committee recommends reimbursement of VAZKEPA ® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular ...
20.07.23 - GlobeNewswire
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
– Agreement Underscores Board’s Commitment to Aligning Executive Compensation with  Shareholder Returns –
19.07.23 - PR Newswire
Thinking about buying stock in Oncolytics Biotech, Amarin Corporation, Biophytis, bluebird bio, or VERSES AI?
Thinking about buying stock in Oncolytics Biotech, Amarin Corporation, Biophytis, bluebird bio, or VERSES AI? PR Newswire
18.07.23 - GlobeNewswire
Amarin Appoints Patrick Holt as President and Chief Executive Officer
DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors ...
18.07.23 - GlobeNewswire
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
-- Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use of Commercial Resources -- -- Maximizes Cash Flow Opportunity Through ...
21.06.23 - GlobeNewswire
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
-- VASCEPA ® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 ...
01.06.23 - GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
-- VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia ...
12.05.23 - GlobeNewswire
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression —
03.05.23 - GlobeNewswire
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives --
19.04.23 - GlobeNewswire
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with ...
17.04.23 - GlobeNewswire
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors ...
04.04.23 - GlobeNewswire
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-​Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk ...
16.03.23 - GlobeNewswire
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
New Amarin Board Believes the Company Will Thrive with Proper Stewardship
06.03.23 - GlobeNewswire
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -–
05.03.23 - GlobeNewswire
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
--Post-​Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding--
01.03.23 - GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-- Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization -- -- Previously Announced Cost Savings Program On-Track to Exceed ...

Newssuche

Videos

07.05.24 +6,80%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »